Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement.DRESDEN, Germany -- Cenix BioScience GmbH, a leading RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. (RNAi)-focused contract research organization, today announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications. The new agreement calls for Cenix to complete at least three major projects applying the same leading platform for RNAi-based research that has now been utilized by major industry clients and partners in the EU and North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . The work will integrate multi-pass genome-scale screens for the discovery of novel therapeutic target candidates with detailed validation analyses, all using a number of primary human cell types. Cenix will adapt assays initially developed by AstraZeneca scientists, combining several complementary technology platforms including automated microscopy microscopy /mi·cros·co·py/ (mi-kros´kah-pe) examination under or observation by means of the microscope. mi·cros·co·py n. 1. The study of microscopes. 2. with Cellenger-based image analysis, to optimize their implementation as high throughput RNAi studies in 384-well and/or 1,536-well formats. "We particularly welcome the approach chosen by AstraZeneca here, of tightly integrating the discovery screens with subsequent validation studies, a strategy that we have been strongly advocating for some years," said Dr. Christophe Echeverri, CEO/CSO of Cenix. "We also greatly appreciate and value the continuing trust that is manifested by this expanded relationship, whose full potential we look forward to realizing together in the months and years to come." Financial terms were not disclosed. NOTES TO EDITORS: About Cenix BioScience GmbH Now in its 10th year, Cenix BioScience is a contract research organization specialized in combining advanced applications of RNAi with high content phenotypic phe·no·type n. 1. a. The observable physical or biochemical characteristics of an organism, as determined by both genetic makeup and environmental influences. b. analyses to enhance and accelerate the discovery and pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. of novel therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . Cenix has built up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields. The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by microRNA-focused experimentation and in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. applications of synthetic siRNAs. As such, Cenix is a mature and fully-proven industrial research provider, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none world wide. For more information, please contact Cenix or visit the company's web site www.cenix-bioscience.com. About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience neu·ro·sci·ence n. Any of the sciences, such as neuroanatomy and neurobiology, that deal with the nervous system. neuroscience the embryology, anatomy, physiology, biochemistry and pharmacology of the nervous system. , respiratory, oncology and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH in the US and other countries. Cellenger is a registered trademark owned by Definiens de·fin·i·ens n. pl. de·fin·i·en·ti·a The word or words serving to define another word or expression, as in a dictionary entry. [Latin d GmbH. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion